PCCG-4 je istraživački lek koji deluje kao selektivni antagonist za grupu II metabotropnih glutamatnih receptora (mGluR2/3), sa neznatnom selektivnošću za mGluR2. Ona nije dovoljna za razlikovanje mGluR2 i mGluR3 responsa. PCCG-4 se koristi u istraživanjima funkcije grupe II metabotropnih glutamatnih receptora.[1][2][3][4][5]
^Pellicciari R, Marinozzi M, Natalini B, Costantino G, Luneia R, Giorgi G, Moroni F, Thomsen C (1996). „Synthesis and pharmacological characterization of all sixteen stereoisomers of 2-(2'-carboxy-3'-phenylcyclopropyl)glycine. Focus on (2S,1'S,2'S,3'R)-2-(2'-carboxy-3'-phenylcyclopropyl)glycine, a novel and selective group II metabotropic glutamate receptors antagonist”. Journal of Medicinal Chemistry. 39 (11): 2259—69. PMID8667369. doi:10.1021/jm960059+.
^Thomsen C, Bruno V, Nicoletti F, Marinozzi M, Pellicciari R (1996). „(2S,1'S,2'S,3'R)-2-(2'-carboxy-3'-phenylcyclopropyl)glycine, a potent and selective antagonist of type 2 metabotropic glutamate receptors”. Molecular Pharmacology. 50 (1): 6—9. PMID8700119.
^Cozzi A, Attucci S, Peruginelli F, Marinozzi M, Luneia R, Pellicciari R, Moroni F (1997). „Type 2 metabotropic glutamate (mGlu) receptors tonically inhibit transmitter release in rat caudate nucleus: in vivo studies with (2S,1'S,2'S,3'R)-2-(2'-carboxy-3'-phenylcyclopropyl)glycine, a new potent and selective antagonist”. The European Journal of Neuroscience. 9 (7): 1350—5. PMID9240392.
^Ciccarelli R, Di Iorio P, Bruno V, Battaglia G, D'Alimonte I, D'Onofrio M, Nicoletti F, Caciagli F (1999). „Activation of A(1) adenosine or mGlu3 metabotropic glutamate receptors enhances the release of nerve growth factor and S-100beta protein from cultured astrocytes”. Glia. 27 (3): 275—81. PMID10457374.
